journal
MENU ▼
Read by QxMD icon Read
search

Cancer Chemotherapy and Pharmacology

journal
https://www.readbyqxmd.com/read/28730293/clinical-predictors-of-survival-in-patients-with-castration-resistant-prostate-cancer-receiving-sipuleucel-t-cellular-immunotherapy
#1
Mehmet Asim Bilen, Kenneth R Hess, Sumit K Subudhi, Ana Aparicio, Jeri Kim, Amado J Zurita-Saavedra, John C Araujo, Paul G Corn, Jessica Stover, Sue-Hwa Lin, Christopher J Logothetis, Shi-Ming Tu
BACKGROUND: We evaluated the patterns of progression and determined clinical predictors of survival in patients with castration-resistant prostate cancer (CRPCa) who received sipuleucel-T. METHODS: We retrospectively analyzed 56 consecutive patients with asymptomatic or minimally symptomatic CRPCa treated with sipuleucel-T. Age, number of bone metastases, history of prior systemic treatment, and alkaline phosphatase level (ALP) were tested as predictors of survival in a multivariate Cox proportional hazards regression model...
July 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28730292/efficacy-and-safety-of-taxane-monotherapy-in-advanced-gastric-cancer-refractory-to-triplet-chemotherapy-with-docetaxel-cisplatin-and-s-1-a-multicenter-retrospective-study
#2
Sakura Iizumi, Atsuo Takashima, Yukiya Narita, Masahiro Tajika, Kei Muro, Sadayuki Kawai, Hirofumi Yasui, Tomohiro Matsushima, Daisuke Takahari, Kengo Nagashima, Narikazu Boku
PURPOSE: Taxane monotherapy is widely used for advanced gastric cancer (AGC) after failure of standard first-line chemotherapy with fluoropyrimidine and cisplatin. Triplet chemotherapy with docetaxel, cisplatin, and S-1 (DCS) is a promising regimen for first-line chemotherapy of AGC. The aim of this study was to evaluate the efficacy of taxane monotherapy in patients refractory to DCS. METHODS: We retrospectively evaluated the efficacy and safety of taxane monotherapy in patients with AGC refractory to first-line therapy with DCS between January 2010 and April 2015...
July 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28730291/electrolyte-disorders-with-platinum-based-chemotherapy-mechanisms-manifestations-and-management
#3
REVIEW
Bryan Oronsky, Scott Caroen, Arnold Oronsky, Vaughn E Dobalian, Neil Oronsky, Michelle Lybeck, Tony R Reid, Corey A Carter
Platinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, hypokalemia, hypophosphatemia, hypocalcemia and hyponatremia. The corpus of literature on these dyselectrolytemias is large; the objective of this review is to synthesize the literature and summarize the mechanisms responsible for these particular electrolyte disturbances in the context of platinum-based treatment as well as to present the clinical manifestations and current management strategies for oncologists and primary care physicians, since the latter are increasingly called on to provide care for cancer patients with medical comorbidities...
July 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28730290/a-phase-i-study-to-investigate-the-metabolism-excretion-and-pharmacokinetics-of-14-c-fruquintinib-a-novel-oral-selective-vegfr-inhibitor-in-healthy-chinese-male-volunteers
#4
Sufeng Zhou, Feng Shao, Zhaoqiang Xu, Lu Wang, Ke Jin, Lijun Xie, Juan Chen, Yun Liu, Hongwen Zhang, Ning Ou
PURPOSE: Fruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors (1, 2 and 3). This study was conducted to investigate the metabolism, excretion, and pharmacokinetics of HMPL-013 after a single oral dose to healthy Chinese men. METHODS: Six subjects were administrated an oral suspension containing 5 mg of (14)C-labeled HMPL-013 (100 μCi) in a fasted state. Blood and excreta samples were collected at the designated time points or intervals for pharmacokinetics and radiometric analyses...
July 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28726081/psoas-muscle-volume-as-a-predictor-of-peripheral-neurotoxicity-induced-by-primary-chemotherapy-in-ovarian-cancers
#5
Tomoyuki Yoshikawa, Masashi Takano, Morikazu Miyamoto, Isao Yajima, Yukihiro Shimizu, Yusuke Aizawa, Yuki Suguchi, Miki Moriiwa, Tadashi Aoyama, Hiroaki Soyama, Tomoko Goto, Junko Hirata, Ayako Suzuki, Hidenori Sasa, Isao Nagaoka, Hitoshi Tsuda, Kenichi Furuya
PURPOSE: Low skeletal muscle mass (sarcopenia) has been reported to have an influence on survival and toxicities of chemotherapy in several solid tumors. The impact of sarcopenia on the treatment of ovarian cancers has not been determined. The present study aimed to evaluate correlation between sarcopenia and toxicities of chemotherapy in ovarian cancers. METHODS: Medical charts of the ovarian cancer patients that received chemotherapy with paclitaxel and carboplatin at our hospital between 2010 and 2015 were retrospectively reviewed...
July 19, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28721456/antiangiogenic-tyrosine-kinase-inhibitors-in-colorectal-cancer-is-there-a-path-to-making-them-more-effective
#6
REVIEW
Thomas B Karasic, Mark A Rosen, Peter J O'Dwyer
Antiangiogenic therapy has a proven survival benefit in metastatic colorectal cancer. Inhibition of the VEGF pathway using a variety of extracellular antibody approaches has clear benefit in combination with chemotherapy, while intracellular blockade using tyrosine kinase inhibitors (TKIs) such as sorafenib and regorafenib has had more limited success. Pharmacodynamic modeling using modalities such as DCE-MRI indicates potent antiangiogenic effects of these TKIs, yet numerous combination therapies, primarily with chemotherapy, have failed to demonstrate an additive benefit...
July 18, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28718011/case-series-on-the-association-between-blood-levels-and-side-effects-of-afatinib-maleate
#7
Junya Sato, Naoto Morikawa, Ryosuke Chiba, Satoru Nihei, Satoshi Moriguchi, Heisuke Saito, Kohei Yamauchi, Kenzo Kudo
PURPOSE: Afatinib maleate (AFA) is a second-generation, tyrosine kinase inhibitor (TKI) treatment for specific variants of non-small cell lung cancer exhibiting epidermal growth factor receptor (EGFR) mutations. In this study, we measured the blood AFA levels in six patients with lung cancer and investigated the association between blood levels and side effects of this drug. METHODS: The study subjects were patients who were administered AFA for non-small cell lung cancer...
July 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28711984/clarithromycin-co-administration-does-not-increase-irinotecan-cpt-11-toxicity-in-colorectal-cancer-patients
#8
Katsuya Makihara, Sayaka Nakamura, Kazuyo Miyagi, Hiroyuki Ueno, Izumi Nakata
PURPOSE: Irinotecan (CPT-11) is used to treat advanced colorectal cancer. The drug is activated by carboxylesterases and rendered inactive by CYP3A4. Recently, the efficacy of combining CPT-11 and anti-epidermal growth factor receptor (EGFR) agents was confirmed in patients with KRAS wild-type metastatic colorectal cancer. Clarithromycin (CAM) is a strong CYP3A inhibitor often used to prevent rash associated with anti-EGFR therapy. The objective of this study was to evaluate the risk of increased neutropenia and diarrhea in combining CPT-11 and CAM...
July 15, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28707014/doxycycline-and-its-quaternary-ammonium-derivative-for-adjuvant-therapies-of-chondrosarcoma
#9
Imen Miladi, Magali Vivier, Marie-Mélanie Dauplat, Morgane Chatard, Sophie Besse, Aurélien Vidal, Karine Chassain, Betty Jean, Christiane Forestier, Jean-Michel Chezal, Francoise Rédini, Francoise Degoul, Elisabeth Miot-Noirault
PURPOSE: This study was conducted during the development of innovative treatment targeting the microenvironment of chondrosarcoma. In this context, MMP inhibitors were conjugated with a quaternary ammonium (QA) function as a targeting ligand to proteoglycans of chondrosarcoma extracellular matrix. Here we report the proof of concept of this strategy applied to the MMP13 inhibitor, doxycycline (Dox). METHODS: A quaternary ammonium derivative of the MMP13 inhibitor doxycycline (QA-Dox) was synthesized, and its anticancer activity was evaluated in the Swarm rat chondrosarcoma (SRC) model compared with the parent drug doxycycline, in vitro and in vivo...
July 13, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28707013/sunitinib-is-effective-and-tolerable-in-chinese-patients-with-advanced-pancreatic-neuroendocrine-tumors-a-multicenter-retrospective-study-in-china
#10
Yuhong Wang, Kaizhou Jin, Huangying Tan, Pan Zhang, Qiuchen Yang, Wei Wang, Jie Li, Chenghao Shao, Ling Xue, Shiting Feng, Minhu Chen, Xianjun Yu, Jie Chen
PURPOSE: To determine the efficacy and safety of sunitinib in Chinese patients with unresectable or metastatic pancreatic neuroendocrine tumors (pNETs) and the clinical significance of steady-state sunitinib serum concentrations. METHODS: We conducted a multicenter retrospective study including six centers from across China. A total of 60 patients with unresectable or metastatic pNETs who were treated with sunitinib were evaluated retrospectively. RESULTS: The median overall survival (OS) was 47...
July 13, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28702772/a-phase-ii-trial-of-erlotinib-monotherapy-in-advanced-pancreatic-cancer-as-a-first-or-second-line-agent
#11
Christos Fountzilas, Ravi Chhatrala, Nikhil Khushalani, Wei Tan, Charles LeVea, Alan Hutson, Chris Tucker, Wen Wee Ma, Graham Warren, Patrick Boland, Renuka Iyer
INTRODUCTION: Pancreatic adenocarcinoma carries a grim prognosis. In 2007, gemcitabine with erlotinib emerged as an appropriate treatment option for patients with advanced inoperable or metastatic disease (APC). In this phase II trial we sought to evaluate the efficacy of erlotinib monotherapy in patients with APC who had disease refractory to or ineligibility for gemcitabine-based therapy. METHODS: Eligible patients who had received 0 or 1 non-EGFR inhibitor containing gemcitabine-based chemotherapy for APC were recruited prospectively and treated with erlotinib 150 mg orally daily until unacceptable toxicity or disease progression...
July 12, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28714036/pharmacokinetics-of-intravenous-pan-class-i-phosphatidylinositol-3-kinase-pi3k-inhibitor-14-c-copanlisib-bay-80-6946-in-a-mass-balance-study-in-healthy-male-volunteers
#12
Michael Gerisch, Thomas Schwarz, Dieter Lang, Gabriele Rohde, Stefanie Reif, Isabelle Genvresse, Susanne Reschke, Dorina van der Mey, Camille Granvil
PURPOSE: To determine the pharmacokinetics of radiolabeled copanlisib (BAY 80-6946) in healthy male volunteers and to investigate the disposition and biotransformation of copanlisib. METHODS: A single dose of 12 mg copanlisib containing 2.76 MBq [(14)C]copanlisib was administered as a 1-h intravenous infusion to 6 volunteers with subsequent sampling up to 34 days. Blood, plasma, urine and feces were collected to monitor total radioactivity, parent compound and metabolites...
July 11, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28695268/risk-of-venous-and-arterial-thromboembolic-events-associated-with-vegfr-tkis-a-meta-analysis
#13
Bo Liu, Fengxia Ding, Deying Zhang, Guang-Hui Wei
The reported incidence of arterial and venous thromboembolic events varies markedly between VEGFR-TKI-related clinical trials. Here, we performed a meta-analysis to determine the incidence and the relative risk (RR) of venous thromboembolism events (VTEs) and arterial thromboembolic events (ATEs) associated with these agents. Databases (PubMed, Web of Science) were searched for relevant studies. Statistical analyses were conducted to calculate the summary incidences, RRs and 95% confidence intervals (CIs) using either random-effects or fixed-effects models according to the heterogeneity of the included studies...
July 10, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28695267/impact-of-an-alternative-steroid-on-the-relative-bioavailability-and-bioequivalence-of-a-novel-versus-the-originator-formulation-of-abiraterone-acetate
#14
Azra Hussaini, Anthony J Olszanski, Cy A Stein, Bill Bosch, Paul Nemeth
PURPOSE: The originator abiraterone acetate (OAA) formulation is used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the bioavailability and bioequivalence of a novel formulation, abiraterone acetate fine particle (AAFP), versus OAA on a steady-state background of steroids. METHODS: Thirty-seven healthy male subjects were randomized in a crossover design to receive methylprednisolone (4 mg twice daily) or prednisone (5 mg twice daily) for 12 days in Period 1...
July 10, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28689298/short-infusion-of-paclitaxel-imbalances-plasmatic-lipid-metabolism-and-correlates-with-cardiac-markers-of-acute-damage-in-patients-with-breast-cancer
#15
C Panis, R Binato, S Correa, V J Victorino, V Dias-Alves, A C S A Herrera, R Cecchini, A N C Simão, D S Barbosa, L Pizzatti, E Abdelhay
PURPOSE: Although paclitaxel-based chemotherapy is widely used for treating breast cancer, paclitaxel therapy has been associated with several adverse effects. Such adverse effects have primarily been associated with long-term regimens, but some acute effects are being increasingly reported in the literature. In this context, the present study analyzed the systemic proteomic profiles of women diagnosed with breast cancer at the first cycle of short paclitaxel infusion (n = 30). Proteomic profiles thus obtained were compared with those of breast cancer patients without chemotherapy (n = 50), as well as with those of healthy controls (n = 40)...
July 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28688052/carboplatin-plus-weekly-nanoparticle-albumin-bound-paclitaxel-in-elderly-patients-with-previously-untreated-advanced-squamous-non-small-cell-lung-cancer-selected-based-on-mini-nutritional-assessment-short-form-scores-a-multicenter-phase-2-study
#16
Takayuki Shiroyama, Motohiro Tamiya, Seigo Minami, So Takata, Kentaro Masuhiro, Yu Futami-Nishijima, Takeshi Uenami, Masahide Mori, Taro Koba, Takanori Matsuki, Takayuki Takimoto, Hidekazu Suzuki, Norio Okamoto, Kiyoshi Komuta, Tomonori Hirashima, Atsushi Kumanogoh, Takashi Kijima
PURPOSE: This multicenter, single-arm, open-label, phase 2 study assessed the efficacy and safety of carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer, selected based on the Mini Nutritional Assessment short-form scores (MNA-SF). METHODS: Patients received carboplatin (area under the curve: 6) on Day 1, and nanoparticle albumin-bound paclitaxel (100 mg/m(2)) on Days 1, 8, and 15, every 28 days for ≤4 cycles...
July 7, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28685347/potential-for-a-novel-manganese-porphyrin-compound-as-adjuvant-canine-lymphoma-therapy
#17
M K Boss, M W Dewhirst, R S Sampaio, A Bennett, A Tovmasyan, K G Berman, A W Beaven, D A Rizzieri, I Batinic-Haberle, M L Hauck, I Spasojevic
PURPOSE: Manganese porphyrins are redox-active drugs and superoxide dismutase mimics, which have been shown to chemosensitize lymphoma, a cancer which frequently occurs in dogs. This study aimed to identify critical information regarding the pharmacokinetics and toxicity of Mn(III) meso-tetrakis (N-n-butoxyetylpyridium-2-yl) porphyrin, (MnTnBuOE-2-PyP(5+), MnBuOE) in dogs as a prelude to a clinical trial in canine lymphoma patients. METHODS: A single-dose pharmacokinetic (PK) study in normal dogs was performed to determine the plasma half-life (t 1/2) of MnBuOE...
July 6, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28685346/hinokitiol-suppresses-cancer-stemness-and-oncogenicity-in-glioma-stem-cells-by-nrf2-regulation
#18
Wen-Chen Ouyang, Yi-Wen Liao, Pei-Ni Chen, Kai-Hsi Lu, Cheng-Chia Yu, Pei-Ling Hsieh
PURPOSE: Glioma is one of the lethal malignancies with poor prognosis. In addition, glioma stem cells (GSCs) have been considered as the crucial player that attributed to the tumorigenesis and drug resistance. In the current study, we investigated the therapeutic effect of hinokitiol, a natural bioactive compound of aromatic tropolone, on the characteristics of GSCs and the possible mechanism. METHODS: U87MG and T98G glioma cells were used to isolate GSCs. CD133 positivity and ALDH1 activity of GSCs following hinokitiol treatment were assessed by flow cytometry analysis...
July 6, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28676933/association-of-nr1i2-cyp3a5-and-abcb1-genetic-polymorphisms-with-variability-of-temsirolimus-pharmacokinetics-and-toxicity-in-patients-with-metastatic-bladder-cancer
#19
Litaty C Mbatchi, Matthieu Gassiot, Philippe Pourquier, Alejando Goberna, Hakim Mahammedi, Loic Mourey, Florence Joly, Serge Lumbroso, Alexandre Evrard, Nadine Houede
PURPOSE: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor that exhibits antitumor activity in renal cell carcinoma and mantle cell lymphoma. The metabolism of temsirolimus and its active metabolite sirolimus mainly depends on cytochrome P450 3A4/5 (CYP3A4/A5) and the ABCB1 transporter. Differently from sirolimus, no pharmacogenetic study on temsirolimus has been conducted. Therefore, the aim of this pilot study was to identify genetic determinants of the inter-individual variability in temsirolimus pharmacokinetics and toxicity...
July 4, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28669065/consolidation-hyperthermic-intraperitoneal-chemotherapy-for-the-treatment-of-advanced-stage-ovarian-carcinoma-a-3%C3%A2-year-experience
#20
Alberto A Mendivil, Mark A Rettenmaier, Lisa N Abaid, John V Brown, Kristina M Mori, Katrina L Lopez, Bram H Goldstein
PURPOSE: Hyperthermic intraperitoneal chemotherapy (HIPEC) potentially confers significant survival benefits in the management of ovarian cancer although the long-term data remain scant. We sought to compare the survival rates of advanced stage ovarian cancer patients who were treated with primary induction therapy alone or in conjunction with consolidation HIPEC. METHODS: 69 ovarian cancer patients who underwent surgery and completed their primary induction chemotherapy were treated with consolidation carboplatin (AUC 10) based HIPEC and compared to a historical cohort that received surgery and primary chemotherapy alone (n = 69)...
July 1, 2017: Cancer Chemotherapy and Pharmacology
journal
journal
27426
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"